{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:34:03Z","timestamp":1773747243987,"version":"3.50.1"},"reference-count":58,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicines"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce morbidity and mortality associated with type II diabetes mellitus, and\/or obesity, and\/or cardiovascular disease in multiple clinical trials. Their efficacy in reversing cardiovascular disease and mitigating the risk of major adverse cardiac and vascular events has been well studied, with outcome trials consistently demonstrating benefits such as reduced systemic inflammation, improved endothelial function, and favorable metabolic effects. These pleiotropic actions have nearly innumerable potential applications, with a progressively growing interest in using GLP-1 RAs to mitigate increased cardiovascular disease risk secondary to other off-target pharmacologic agents. Given these effects, the potential to utilize GLP-1 RAs for prophylactic cardioprotection before, during, and\/or after chemotherapy regimens is of great interest. These effects are thought to be mediated in part through anti-inflammatory and antioxidant mechanisms that counter inflammation and reactive oxygen species-driven myocardial injury central to anthracycline-induced cardiotoxicity (AIC). Anthracyclines, a widely used class of chemotherapeutics for various malignancies, are frequently associated with dose-dependent and often irreversible cardiotoxicity, leading to heart failure, reduced quality of life, and adverse long-term outcomes. For the past three decades, dexrazoxane has been the sole Food and Drug Administration-approved agent for cardioprotection in this setting. However, in the current era of novel therapies with multi-system benefits\u2014such as GLP-1 RAs\u2014we propose a theoretical framework exploring their potential role in mitigating AIC and underscore the need for further clinical investigation in this new arena in the field of cardio-oncology.<\/jats:p>","DOI":"10.3390\/medicines13010010","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:21:41Z","timestamp":1773742901000},"page":"10","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Pleiotropic Cardioprotective Effects of GLP-1 Receptor Agonists in Preventing Anthracycline-Induced Cardiotoxicity: A Theoretical Proposal for Future Research"],"prefix":"10.3390","volume":"13","author":[{"given":"Matthew L.","family":"Repp","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1674-8270","authenticated-orcid":false,"given":"Ikeotunye Royal","family":"Chinyere","sequence":"additional","affiliation":[{"name":"Sarver Heart Center, University of Arizona, 1501 North Campbell Avenue, Room 6154, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Teran","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Bast","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-2296","authenticated-orcid":false,"given":"Lavanya","family":"Kondapalli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07388558509150782","article-title":"Anthracycline antibiotics","volume":"3","author":"Fujiwara","year":"1985","journal-title":"Crit. Rev. Biotechnol."},{"key":"ref_2","unstructured":"(2025, December 02). Doxorubicin FDA Approval, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/050467s078,050629s030lbl.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"ref_5","first-page":"214","article-title":"Anthracycline cardiotoxicity: Prevalence, pathogenesis and treatment","volume":"7","author":"Volkova","year":"2012","journal-title":"Curr. Cancer Drug Targets (CCR)"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","article-title":"American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects","volume":"25","author":"Carver","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_9","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"9","author":"Caron","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40959-024-00260-y","article-title":"Use of EMPAgliflozin in the prevention of CARDiotoxicity: The EMPACARD\u2014PILOT trial","volume":"10","author":"Daniele","year":"2024","journal-title":"Cardio-Oncology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in Heart Failure: JACC State-of-the-Art Review","volume":"75","author":"Murphy","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ahj.2006.02.023","article-title":"C-reactive protein and risk of heart failure. The Rotterdam Study","volume":"152","author":"Kardys","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21672","DOI":"10.1038\/s41598-024-72137-0","article-title":"High-sensitivity C-reactive protein and risk of clinical outcomes in patients with acute heart failure","volume":"14","author":"Santas","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Reina-Couto, M., Pereira-Terra, P., Quelhas-Santos, J., Silva-Pereira, C., Albino-Teixeira, A., and Sousa, T. (2021). Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. Front. Physiol., 12.","DOI":"10.3389\/fphys.2021.746494"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/hearts5030027","article-title":"PCSK9 Inhibitors and Anthracyclines: The Future of Cardioprotection in Cardio-Oncology","volume":"5","author":"Repp","year":"2024","journal-title":"Hearts"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI6709","article-title":"Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium","volume":"104","author":"Frantz","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","article-title":"Toll-like receptor signalling","volume":"4","author":"Akira","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cardiores.2006.09.011","article-title":"Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response","volume":"72","author":"Boyd","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2234","DOI":"10.1038\/cddis.2016.140","article-title":"The emerging role of Toll-like receptor 4 in myocardial inflammation","volume":"7","author":"Yang","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejheart.2008.01.004","article-title":"Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice","volume":"10","author":"Riad","year":"2008","journal-title":"Eur. J. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1111\/jcmm.12659","article-title":"Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction","volume":"19","author":"Liu","year":"2015","journal-title":"J. Cell Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbrc.2019.06.015","article-title":"Role of TLR4\/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure","volume":"516","author":"Chen","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1111\/dom.16366","article-title":"The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta-analysis","volume":"27","author":"Ren","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18522","DOI":"10.1038\/s41598-021-97967-0","article-title":"Effect of liraglutide on expression of inflammatory genes in type 2 diabetes","volume":"11","author":"Zobel","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110311","DOI":"10.1016\/j.intimp.2023.110311","article-title":"Tirzepatide attenuates lipopolysaccharide-induced left ventricular remodeling and dysfunction by inhibiting the TLR4\/NF-kB\/NLRP3 pathway","volume":"120","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"R410","DOI":"10.1152\/ajpregu.00083.2024","article-title":"Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4\/MyD88\/NF-\u03baB pathway in diabetic kidney disease","volume":"327","author":"Huang","year":"2024","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","article-title":"Mitochondrial function as a therapeutic target in heart failure","volume":"14","author":"Brown","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0005-2736(01)00371-6","article-title":"Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers","volume":"1514","author":"Parker","year":"2001","journal-title":"BBA Biomembr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e1969","DOI":"10.1038\/cddis.2015.305","article-title":"Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents","volume":"6","author":"Yadav","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1388-1981(02)00329-3","article-title":"Cardiolipin and apoptosis","volume":"1585","author":"McMillin","year":"2002","journal-title":"BBA Mol. Cell Biol. Lipids"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Aryal, B., and Rao, V.A. (2016). Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158376"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"13672","DOI":"10.1038\/s41598-018-31939-9","article-title":"Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells","volume":"8","author":"Karabekmez","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/0041-008X(91)90277-L","article-title":"Increased toxicity of anthracycline antibiotics induced by calcium entry blockers in cultured cardiomyocytes","volume":"108","author":"Santostasi","year":"1991","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1074\/jbc.M308033200","article-title":"Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes","volume":"279","author":"Lim","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"109252","DOI":"10.1016\/j.cbi.2020.109252","article-title":"GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1\u03b2-induced metabolic disturbance and mitochondrial dysfunction","volume":"332","author":"Zhang","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.7150\/ijbs.27774","article-title":"GLP-1 treatment protects endothelial cells from oxidative stress-induced autophagy and endothelial dysfunction","volume":"14","author":"Cai","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8008","DOI":"10.1038\/s41598-017-06712-z","article-title":"GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.2337\/db15-0084","article-title":"GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop","volume":"64","author":"Giacco","year":"2015","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.atherosclerosis.2015.03.026","article-title":"GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats","volume":"240","author":"Inoue","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2015.01.002","article-title":"Association of low GLP-1 with oxidative stress is related to cardiac disease and outcome in patients with type 2 diabetes mellitus: A pilot study","volume":"81","author":"Ravassa","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102849","DOI":"10.1016\/j.redox.2023.102849","article-title":"Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes","volume":"66","author":"Hermenejildo","year":"2023","journal-title":"Redox Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/CMAR.S468453","article-title":"Effects of Semaglutide in Doxorubicin-Induced Cardiac Toxicity in Wistar Albino Rats","volume":"16","author":"HamaSalih","year":"2024","journal-title":"Cancer Manag. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Wu, L., Qin, Y., Zheng, X.L., Zhang, G., Zhou, Q., and Liu, L. (2025). Glucagon-like peptide-1 (GLP-1) Prevents Doxorubicin-Induced Cardiotoxicity by Regulating Macrophage Polarization. Res. Sq., rs-5713487.","DOI":"10.21203\/rs.3.rs-5713487\/v1"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103129","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ijcard.2017.01.123","article-title":"Enhanced-autophagy by exenatide mitigates doxorubicin-induced cardiotoxicity","volume":"232","author":"Lee","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s00210-017-1414-z","article-title":"Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt\/GSK-3\u03b2 signaling pathway","volume":"390","author":"Abbas","year":"2017","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"171245","DOI":"10.1016\/j.peptides.2024.171245","article-title":"Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K\/Akt signaling","volume":"178","author":"Chen","year":"2024","journal-title":"Peptides"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Tonon, C.R., Monte, M.G., Balin, P.S., Fujimori, A.S.S., Ribeiro, A.P.D., Ferreira, N.F., Vieira, N.M., Cabral, R.P., Okoshi, M.P., and Okoshi, K. (2024). Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115833"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"12026","DOI":"10.1200\/JCO.2024.42.16_suppl.12026","article-title":"The impact of glucagon-like peptide 1 agonists on anthracycline or human epidermal growth factor receptor 2 inhibitor-associated cardiotoxicity in patients with breast cancer and diabetes mellitus","volume":"42","author":"Chang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4145444","DOI":"10.1161\/circ.150.suppl_1.4145444","article-title":"Abstract 4145444: GLP-1 Receptor Agonists And Clinical Events After Anthracycline-Based Chemotherapy: A Propensity Score-Matched Cohort Study","volume":"150","author":"Felix","year":"2024","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40959-025-00381-y","article-title":"Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction","volume":"11","author":"Scalia","year":"2025","journal-title":"Cardio-Oncology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e040919","DOI":"10.1161\/JAHA.125.040919","article-title":"Role of GLP-1 Receptor Agonists in Managing Cancer Therapy\u2013Related Cardiac Dysfunction","volume":"14","author":"Vignarajah","year":"2025","journal-title":"J. Am. Heart Assoc."}],"container-title":["Medicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/1\/10\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:48:53Z","timestamp":1773744533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6320\/13\/1\/10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["medicines13010010"],"URL":"https:\/\/doi.org\/10.3390\/medicines13010010","relation":{},"ISSN":["2305-6320"],"issn-type":[{"value":"2305-6320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]}}}